Novo Nordisk rolls out its Wegovy pill in the United Arab Emirates (UAE), marking the first market outside the United States for the oral form of the obesity drug. The company describes the launch as part of its broader plan to expand globally using “patient demand” and the availability of healthcare and telehealth infrastructure as key factors. The company’s guidance indicates it will sequence additional country launches based on local demand signals and the systems needed to support prescribing, access, and follow-up care for patients taking Wegovy in pill form. While the outlets agree on the UAE launch and its status as the first outside the U.S., they provide limited additional detail on pricing, eligibility criteria, or timelines for other markets. Overall, the reporting frames the UAE roll-out as a step in Novo Nordisk’s international expansion strategy for the oral version of Wegovy, with infrastructure readiness and patient needs driving where and when the product becomes available.